All CoverageEndometrial and Uterine CancersKey Endometrial Cancer Data From SGO 2024Ursula A. Matulonis, MDVideoUrsula A. Matulonis, MD, breaks down results from the pivotal RUBY and NRG GY018 trials, which she says are “very much practice-changing.” Endometrial and Uterine CancersKey Endometrial Cancer Data From SGO 2024Ursula A. Matulonis, MDVideoUrsula A. Matulonis, MD, breaks down results from the pivotal RUBY and NRG GY018 trials, which she says are “very much practice-changing.” Breast CancerWhen to Treat Non-TNBC Like It’s TNBC?Erin Frances Cobain, MD, Manali Bhave, MD, Stephanie Graff, MDVideoOur panel discusses how data in very low HR-positive, HER2-negative early-stage breast cancer have led to questions about if it should be treated like TNBC. Breast CancerWhen to Treat Non-TNBC Like It’s TNBC?Erin Frances Cobain, MD, Manali Bhave, MD, Stephanie Graff, MDVideoOur panel discusses how data in very low HR-positive, HER2-negative early-stage breast cancer have led to questions about if it should be treated like TNBC. Urothelial CarcinomaLessons From the Bladder Cancer Drug ShortageElizabeth Guancial, MDVideoElizabeth Guancial, MD, discusses how the recent chemotherapy drug shortage affected bladder cancer care and what may help with such situations in the future. Urothelial CarcinomaLessons From the Bladder Cancer Drug ShortageElizabeth Guancial, MDVideoElizabeth Guancial, MD, discusses how the recent chemotherapy drug shortage affected bladder cancer care and what may help with such situations in the future. Hepatocellular Carcinoma (HCC)Paradigm Shift in Liver Cancer on the Horizon?Riccardo Lencioni, MDVideoRiccardo Lencioni, MD, discusses EMERALD-1 results, which he says have “opened a new horizon” in liver cancer and point to a paradigm shift soon. Hepatocellular Carcinoma (HCC)Paradigm Shift in Liver Cancer on the Horizon?Riccardo Lencioni, MDVideoRiccardo Lencioni, MD, discusses EMERALD-1 results, which he says have “opened a new horizon” in liver cancer and point to a paradigm shift soon. Breast CancerMaximizing Outcomes in HR+/HER2- Breast CancerJanice Lu, MD, PhDVideoJanice Lu, MD, PhD, discusses three abstracts that can help guide treatment choices for HR+/HER2- breast cancer with mutations in ESR1, PIK3CA, PTEN, or AKT. Breast CancerMaximizing Outcomes in HR+/HER2- Breast CancerJanice Lu, MD, PhDVideoJanice Lu, MD, PhD, discusses three abstracts that can help guide treatment choices for HR+/HER2- breast cancer with mutations in ESR1, PIK3CA, PTEN, or AKT. Lung CancerTop Lung Cancer News From 2023 and 2024 PreviewDevika Das, MD, Charu Aggarwal, MD, MPHVideoWith practice-changing data and new approaches, it was a big year in lung cancer. Devika Das, MD, and Charu Aggarwal, MD, MPH, discuss 2023’s key advances. Lung CancerTop Lung Cancer News From 2023 and 2024 PreviewDevika Das, MD, Charu Aggarwal, MD, MPHVideoWith practice-changing data and new approaches, it was a big year in lung cancer. Devika Das, MD, and Charu Aggarwal, MD, MPH, discuss 2023’s key advances. Non-Hodgkin's Lymphoma (NHL)What New Ibrutinib Data Mean for MCL PracticeMichael Wang, MDVideoMichael Wang, MD, explains how to apply new data that show ibrutinib plus venetoclax improves PFS in R/R MCL, given ibrutinib’s withdrawal in the U.S. Non-Hodgkin's Lymphoma (NHL)What New Ibrutinib Data Mean for MCL PracticeMichael Wang, MDVideoMichael Wang, MD, explains how to apply new data that show ibrutinib plus venetoclax improves PFS in R/R MCL, given ibrutinib’s withdrawal in the U.S. Non-Hodgkin's Lymphoma (NHL)Combo or Sequence BR and BTK Inhibitors in MCL?Yucai Wang, MD, PhDVideoYucai Wang, MD, PhD, discusses whether BTK inhibitor use should be combined with bendamustine-rituximab therapy in frontline treatment of MCL. Non-Hodgkin's Lymphoma (NHL)Combo or Sequence BR and BTK Inhibitors in MCL?Yucai Wang, MD, PhDVideoYucai Wang, MD, PhD, discusses whether BTK inhibitor use should be combined with bendamustine-rituximab therapy in frontline treatment of MCL. Breast CancerImmunotherapy Toxicity: What Oncologists May MissYuan Yuan, MD, PhDVideoYuan Yuan, MD, PhD, shares recent data on immunotherapy toxicity in breast cancer and points to “extremely important” information that clinicians should know. Breast CancerImmunotherapy Toxicity: What Oncologists May MissYuan Yuan, MD, PhDVideoYuan Yuan, MD, PhD, shares recent data on immunotherapy toxicity in breast cancer and points to “extremely important” information that clinicians should know. Breast CancerHow ER-Positive Breast Cancer Care Is ChangingAditya Bardia, MD, MPHVideoAditya Bardia, MD, MPH, discusses what new data mean for neoadjuvant immunotherapy in ER-positive breast cancer and the potential for another ADC approval. Breast CancerHow ER-Positive Breast Cancer Care Is ChangingAditya Bardia, MD, MPHVideoAditya Bardia, MD, MPH, discusses what new data mean for neoadjuvant immunotherapy in ER-positive breast cancer and the potential for another ADC approval. Breast CancerTucatinib’s New Role in HER2+ Breast Cancer?Sara A. Hurvitz, MD, FACPVideoSara A. Hurvitz, MD, FACP, discusses what HER2CLIMB-02 data mean for practice when treating HER2+ breast cancer, specifically patients with brain metastases. Breast CancerTucatinib’s New Role in HER2+ Breast Cancer?Sara A. Hurvitz, MD, FACPVideoSara A. Hurvitz, MD, FACP, discusses what HER2CLIMB-02 data mean for practice when treating HER2+ breast cancer, specifically patients with brain metastases. Breast CancerOK to Skip Radiation in Some Breast Cancers?Reshma Jagsi, MD, DPhilVideoReshma Jagsi, MD, DPhil, discusses five-year data from the IDEA trial that show low recurrence after omitting radiation in certain patients with breast cancer. Breast CancerOK to Skip Radiation in Some Breast Cancers?Reshma Jagsi, MD, DPhilVideoReshma Jagsi, MD, DPhil, discusses five-year data from the IDEA trial that show low recurrence after omitting radiation in certain patients with breast cancer.